Functional genomic analysis of peripheral blood during early acute renal allograft rejection

Transplantation

Volumn 88, Issue 7, 2009, Pages 942-951

  Günther, Oliver P ^a   Balshaw, Robert F ^a   Scherer, Andreas ^b   Hollander, Zsuzsanna ^a   Mui, Alice ^a   Triche, Timothy J ^c   Freue, Gabriela Cohen ^a   Li, Guiyun ^a   Ng, Raymond T ^a   Wilson McManus, Janet ^a   McMaster, W Robert ^a   McManus, Bruce M ^a   Keown, Paul A ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Spheromics ^*  (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute rejection; Biomarkers; Gene expression; Kidney transplantation; Whole blood

Indexed keywords

BASILIXIMAB; MEPREDNISONE; MYCOPHENOLIC ACID; OKT 3; PREDNISONE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BIOPSY TECHNIQUE; BLOOD; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL EVALUATION; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; CYTOSKELETON; FEASIBILITY STUDY; FEMALE; GENE; GENE EXPRESSION PROFILING; GENOME ANALYSIS; HUMAN; IMMUNE RESPONSE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SIGNAL TRANSDUCTION; VALIDATION PROCESS;

ACUTE DISEASE; ANTIBODIES, MONOCLONAL; BIOPSY; CASE-CONTROL STUDIES; DISCRIMINANT ANALYSIS; DNA, COMPLEMENTARY; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENOMICS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PHENOTYPE; PROSPECTIVE STUDIES; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RNA; TIME FACTORS;

EID: 73249144602     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b7ccc6     Document Type: Article

References (68)

1. US Renal Data System U. Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2006.
2. Australia and New Zealand Dialysis and Transplant Registry A. ANZDATA Registry Report 2006. Adelaide, South Australia, Australia and New Zealand Dialysis and Transplant Registry 2006.
3. Canadian Organ Replacement Register C. Treatment of end-stage organ failure in Canada 1995 to 2004. Ottawa, Ontario, Canadian Institute for Health Information 2006.
4. Parasuraman R, Yee J, Karthikeyan V, et al. Infectious complications in renal transplant recipients. Adv Chronic Kidney Dis 2006; 13: 280.
5. Yao G, Albon E, Adi Y, et al. A systematic review and economic model of the clinical and cost-effectiveness of immunosuppressive therapy for renal transplantation in children. Health Technol Assess 2006; 10: iii-iv, ix-xi, 1.
6. Winkelmayer W, Weinstein M, Mittleman M, et al. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002; 22: 417.
7. Keown P. Improving quality of life-The new target for transplantation. Transplantation 2001; 72(12 suppl): S67.
8. Gaston R. Current and evolving immunosuppressive regimens in kidney transplantation. Am J Kidney Dis 2006; 47(4 suppl 2): S3.
9. Zand M. Immunosuppression and immune monitoring after renal transplantation. Semin Dial 2005; 18: 511.
10. Rodrigo E, Arias M. A practical approach to immune monitoring in kidney transplantation. Minerva Urol Nefrol 2007; 59: 337.
11. Girlanda R, Mannon R, Kirk A. Diagnostic tools for monitoring kidney transplant recipients. Semin Nephrol 2007; 27: 462.
12. Furness P, Philpott C, Chorbadjian M, et al. Protocol biopsy of the stable renal transplant: A multicenter study of methods and complication rates. Transplantation 2003; 76: 969.
13. Curtis J. Protocol biopsy: Today's fine-needle aspiration biopsy? Transplantation 2007; 84: 677.
14. Furness P, Taub N, Assmann K, et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003; 27: 805.
15. Gough. J, Rush. D, Jeffery J, et al. Reproducibility of the Banff schema in reporting protocol biopsies of stable renal allografts. Nephrol Dial Transplant 2002; 17: 1081.
16. Gaber L. Role of renal allograft biopsy in multicenter clinical trials in transplantation. Am J Kidney Dis 1998; 31(6 suppl 1): S19.
17. Veronese F, Manfro R, Roman F, et al. Reproducibility of the Banff classification in subclinical kidney transplant rejection. Clin Transplant 2005; 19: 518.
18. Colvin R, Cohen A, Saiontz C, et al. Evaluation of pathologic criteria for acute renal allograft rejection: Reproducibility, sensitivity, and clinical correlation. J Am. Soc Nephrol 1997; 8: 1930.
19. Hayden P, El-Meanawy A, Schelling J, et al. DNA expression analysis: Serial analysis of gene expression, microarrays and kidney disease. Curr Opin Nephrol Hypertens 2003; 12: 407.
20. Henger A, Schmid H, Kretzler M. Gene expression analysis of human renal biopsies: Recent developments towards molecular diagnosis of kidney disease. Curr Opin Nephrol Hypertens 2004; 13: 313.
21. Kurian S, Grigoryev Y, Head S, et al. Applying genomics to organ transplantation medicine in both discovery and validation of biomarkers. hit Immunopharmacol 2007; 7: 1948.
22. Irizarry R, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003; 4: 249.
23. Smyth G, Michaud J, Scott H. Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005; 21: 2067.
24. Gentleman R, Carey V, Bates D, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
25. Sarwal M, Chua M, Kambham N, et al. Molecular heterogeneity in acute renal allograft rejection identified by DNA microarray profiling. N Engl J Med 2003; 349: 125.
26. Einecke G, Reeve J, Mengel M, et al. Expression of B cell and immunoglobulin transcripts is a feature of inflammation in late allografts. Am J Transplant 2008; 8: 1434.
27. Famulski K, Broderick G, Einecke G, et al. Transcriptome analysis reveals heterogeneity in the injury response of kidney transplants. Am J Transplant 2007; 7: 2483.
28. Mueller T, Einedte G, Reeve J, et al. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. Am J Transplant 2007; 7: 2712.
29. Aquino-Dias E, Joelsons G, da Silva D, et al. Non-invasive diagnosis of acute rejection in kidney transplants with delayed graft function. Kidney Int 2008 73: 877.
30. Marrer E, Dieterle F. Promises of biomarkers in drug development - A reality check. Chem Biol Drug Des 2007; 69: 381.
31. Flechner S, Kurian S, Head S, et al. Kidney transplant rejection and tissue injury by gene profiling of biopsies and peripheral blood lymphocytes. Am J Transplant 2004; 4: 1475.
32. Brouard S, Mansfield E, Braud C, et al. Identification of a peripheral blood transcriptional biomarker panel associated with operational renal allograft tolerance. Proc Natl Acad Sci USA 2007; 104: 15448.
33. Le-Niculescu H, Kurian S, Yehyawi N, et al. Identifying blood biomarkers for mood disorders using convergent functional genomics. Mol Psychiatry 2009; 14: 156.
34. Etminan M, Samii A. Pharmacoepidemiology I: A review of pharmacoepidemiologic study designs. Pharmacotherapy 2004; 24: 964.
35. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
36. Smyth GK. Limma: Linear models for microarray data. In: Gentleman R, Carey V, Dudoit S, et al eds. Bioinformatics and computational biology solutions using R and bioconductor. NY, Springer 2005, pp 397.
37. Tusher V, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116.
38. Hennighausen L, Robinson G. Interpretation of cytokine signaling through the transcription factors STAT5A and STAT5B. Genes Dev 2008; 22: 711.
39. Zhou P, Szot G, Guo Z, et al. Role of STAT4 and STAT6 signaling in allograft rejection and CTLA4-Ig-mediated tolerance. J Immunol 2000; 165: 5580.
40. Hidalgo L, Halloran P. Role of IFN-gamma in allograft rejection. Crit Rev Immunol 2002; 22: 317.
41. + cells by Fas/Fas-ligand interaction. Scientific World J 2002; 2: 421.
42. Cannon J, Burkhardt J. The regulation of actin remodeling during Tcell-APC conjugate formation. Immunol Rev 2002; 186: 90.
43. Burbach B, Medeiros R, Mueller K, et al. T-cell receptor signaling to integrins. Immunol Rev 2007; 218: 65.
44. Peterson E. The TCR ADAPts to integrin-mediated cell adhesion. Immunol Rev 2003; 192: 113.
45. Ivaska J, Bosca L, Parker P. PKCepsilon is a permissive link in integrindependent IFN-gamma signalling that facilitates JAK phosphorylation of STAT1. Nat Cell Biol 2003; 5: 363.
46. Silacci P, Mazzolai L, Gauci C, et al. Gelsolin superfamily proteins: Key regulators of cellular functions. Cell Mol Life Sci 2004; 61: 2614.
47. Kim H, Jiang X, Du F, et al. PHAPI, CAS, and Hsp70 promote apoptosome formation by preventing Apaf-1 aggregation and enhancing nucleotide exchange on Apaf-1. Mol Cell 2008; 30: 239.
48. Stelzl U, Worm U, Lalowski M, et al. A human protein-protein interaction network: A resource for annotating the proteome. Cell 2005; 122: 957.
49. von Gunten S, Yousefi S, Seitz M, et al. Siglec-9 transduces apoptotic and nonapoptotic death signals into neutrophils depending on the proinflammatory cytokine environment. Blood 2005; 106: 1423.
50. Ikehara Y, Ikehara S, Paulson J. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9. J Biol Chem 2004; 279: 43117.
51. Prohl C, Pelzer W, Diekert K, et al. The yeast mitochondrial carrier Leu5p and its human homologue Graves' disease protein are required for accumulation of coenzyme A in the matrix. Mol Cell Biol 2001; 21: 1089.
52. Geirsson A, Paliwal I, Lynch R, et al. Class II transactivator promoter activity is suppressed through regulation by a trophoblast noncoding RNA. Transplantation 2003; 76: 387.
53. Geirsson A, Lynch R, Paliwal I, et al. Human trophoblast noncoding RNA suppresses CIITA promoter III activity in murine B-lymphocytes. Biochem Biophys Res Commun 2003; 301: 718.
54. Geirsson A, Bothwell A, Hammond G. Inhibition of alloresponse by a human, trophoblast non-coding RNA suppressing class II transactivator promoter III and major histocompatibility dass II expression in murine B-lymphocytes. J Heart Lung Transplant 2004; 23: 1077.
55. Adamsen B, Kravik K, Clausen O, et al. Apoptosis, cell cyde progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment, Int J Oncol 2007; 31: 1491.
56. Zhong Z, Wan B, Qiu Y, et al. Identification of a novel human zinc finger gene, ZNF438, with transcription inhibition activity. J Biochem Mol Biol 2007; 40: 517.
57. Chen B, Wu W, Ho F, et al. Inhibition of interleukin-lbeta -induced NF-kappa B activation by calcium/calmodulin-dependent protein kinase kinase occurs through Akt activation associated with interleukin-1 receptor-associated kinase phosphorylation and uncoupling of MyD88. J Biol Chem 2002; 277: 24169.
58. Schlottmann S, Buback F, Stahl B, et al. Prolonged classical NF-kappaB activation prevents autophagy upon E. coli stimulation in vitro: A potential resolving mechanism of inflammation. Mediators Inflamm 2008; 2008: 725854.
59. Knarr G, Kies U, Bell S, et al. Interaction of the chapetone BiP with an antibody domain: Implications for the chapetone cycle. J Mol Biol 2002; 318: 611.
60. Nawa D, Shimada O, Kawasaki N, et al. Stable interaction of the cargo receptor VIP36 with molecular chaperone BiP. Glycobiology 2007; 17: 913.
61. Takano S, Ando T, Hiramatsu N, et al. T cell receptor-mediated signaling induces GRP78 expression in T cells: The implications in maintaining T cell viability. Biochem Biophys Res Commun 2008; 371: 762.
62. Banno A, Ginsberg M. Integrin activation. Biochem Soc Trans 2008; 36(pt2):229.
63. Parmo-Cabafias M, Garda-Bernal D, García-Verdugo R, et al. Intracellular signaling required for CCL25-stimulated T cell adhesion mediated by the integrin alpha4beta1.J Leufcoc Bio 2007;82 380
64. + regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. Am J Pathol 2008; 173: 154.
65. Loyer P, Trembley J, Grenet J, et al. Characterization of cyclin L1 and L2 interactions with CDK11 and splicing factors: Influence of cyclin L isoforms on splice site selection. J Biol Chem 2008; 283: 7721.
66. Loyer P, Trembley J, Katona R, et al. Role of CDK/cyclin complexes in transcription and RNA splicing. Cell Signal 2005; 17: 1033.
67. Puri T, Quigg R. The many effects of complement C3- and C5-binding proteins in renal injury. Semin Nephrol 2007; 27: 321.
68. Famulski K, Sis B, Billesberger L, et al. Interferon-gamma and donor MHC dass I control alternative macrophage activation and activin expression in rejecting kidney allografts: A shift in the Th1-Th2 paradigm. Am J Transplant 2008; 8: 547. (Pubitemid 351287549)